The pathway is a strategic decision
A 510(k) route depends on substantial equivalence to a suitable predicate. De Novo is for novel low-to-moderate risk devices where no suitable predicate exists.
For software and AI products, the pathway decision should be made alongside claims, architecture, performance evidence and risk controls.
The early decision matters
Most regulatory delays begin before the formal assessment. They start when the product, claims, users and evidence expectations are not aligned early enough.
For a startup or scale-up, the goal is not to build every possible compliance artefact immediately. The goal is to know which decisions unblock credible market access and which work can mature later.
Avoid the expensive detour
Teams can lose months by assuming the route before testing the predicate and evidence story. A short pathway assessment can expose whether the route is credible before the submission build begins.
The same exercise also helps international planning because it reveals which evidence can travel and which market-specific expectations need specialist support.
The predicate question is also a product strategy question
A 510(k) strategy depends on more than finding a superficially similar device. The predicate has to support the intended use, technological characteristics and performance story. For software and AI products, a weak predicate argument can quickly become a costly detour.
The right question is not simply 'can we find a predicate?' It is whether the predicate supports the product you actually want to commercialise. If the team has to narrow claims, alter architecture or generate unexpected evidence to fit the route, the business case may change.
Novelty can be an asset or a burden
De Novo can be the right path for novel low-to-moderate risk devices, but it asks the company to establish a new classification and special controls. That can create a more suitable regulatory foundation, especially where software behaviour or AI functionality does not map cleanly to an existing predicate.
The trade-off is time, evidence depth and uncertainty. Teams should understand that trade-off before fundraising, commercial planning or partner commitments assume a route. A pathway assessment can make those assumptions explicit.
Evidence should be shaped before submission writing begins
A submission is not the place to discover that performance testing, cybersecurity, human factors, clinical validation or software documentation do not support the chosen route. The pathway decision should be made while the team can still shape product claims and evidence generation.
This is especially true for AI-enabled software, where data representativeness, model performance, change control and monitoring may become central to the review conversation. The evidence plan should anticipate those questions, not respond to them under pressure.
International planning changes the decision
A US pathway choice can influence how evidence is packaged for the UK, EU, Canada, Australia and Brazil. It does not determine those routes, but it can either create reusable evidence architecture or produce a file that has to be rebuilt for every market.
Neural Vibe’s view is to make the first pathway decision with future market reuse in mind. That does not mean overbuilding the first submission. It means understanding which evidence will travel and where local specialist support will be needed.